Last edition
News about "Spiro Gavaris, President of US Generics at Lupin"
Lupin Launches Risperidone Extended-Release Injectable with 180-day CGT Exclusivity in the US
Risperidone Long-Acting Injectable is Lupin’s first product using its proprietary PrecisionSphere technology developed by its subsidiary Nanomi.
Spiro Gavaris, President Of US Generics At Lupin | 14/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members